Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients.
about
Target margins in radiotherapy of prostate cancerA novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy.An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer.Assessing dose contribution to pelvic lymph nodes in intracavitary brachytherapy for cervical cancer.Dosimetric evaluation of three adaptive strategies for prostate cancer treatment including pelvic lymph nodes irradiation.'Compromise position' image alignment to accommodate independent motion of multiple clinical target volumes during radiotherapy: A high risk prostate cancer example.A Noninvasive Body Setup Method for Radiotherapy by Using a Multimodal Image Fusion Technique.
P2860
Q36067678-295A741D-7E6B-498F-B678-B10B4D449419Q38640375-8E7465DF-721F-4365-B416-069627FA75F3Q41515385-B2D65A75-BFD5-44FF-92F2-D0FBAB4DFFCFQ41689163-46DAF1EE-E7E6-44E7-A605-EF1E97AD58EBQ48711336-31243477-476A-4ED1-AF8F-D180C7E172F6Q49011220-0DB5D21D-8F29-4AC7-AF32-40915FAB3A8AQ49294585-9E2E0781-6CB8-4F26-AC25-29BABA7D0D53
P2860
Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Optimal planning target volume ...... risk prostate cancer patients.
@en
Optimal planning target volume ...... risk prostate cancer patients.
@nl
type
label
Optimal planning target volume ...... risk prostate cancer patients.
@en
Optimal planning target volume ...... risk prostate cancer patients.
@nl
prefLabel
Optimal planning target volume ...... risk prostate cancer patients.
@en
Optimal planning target volume ...... risk prostate cancer patients.
@nl
P2093
P2860
P356
P1433
P1476
Optimal planning target volume ...... risk prostate cancer patients.
@en
P2093
Benjamin K Hinton
John B Fiveash
Michael C Dobelbower
Robert Y Kim
Rojymon Jacob
P2860
P304
P356
10.1155/2013/941269
P577
2013-03-07T00:00:00Z